Harnessing Humanized Mouse Models

‍

Preclinical Disease Models That Deliver Better Predictive Power

‍

In Part 1 of this series, we explored the translational gap that continues to undermine drug development and clinical success, highlighting how humanized mouse models have emerged as a pivotal solution. These sophisticated models, by more accurately reflecting human biology, offer researchers and biotech developers a powerful tool to de-risk therapeutic strategies and align preclinical research with clinical outcomes. In this second piece, we shift the focus inside the immune system of the humanized mouse to uncover the technological breakthroughs that have made these models indispensable for immunology, vaccine development, and autoimmune disease research.

‍

Part 2: Inside the Humanized Mouse: Engineering the Human Immune System

‍

A cornerstone of these advances lies in HLA class I and II knock-in technologies, which have dramatically improved the physiological relevance of humanized immune responses. Unlike older HLA transgenic mice—where expression was often unpredictable and interfered with by endogenous murine MHC—knock-in models precisely replace mouse MHC genes with human counterparts, eliminating artifacts and enabling tightly regulated, tissue-appropriate expression. A transformative example is the monochain HLA class I knock-in design, where the α1/α2 domains of specific human HLA-A allotypes (such as HLA-A0201, A0301, A2402, and A3101) are fused with the α3 domain of mouse H-2Db and covalently linked to human β2-microglobulin. These constructs are inserted directly into the endogenous mouse β2M locus, ensuring that gene dosage and expression patterns mirror those observed in human peripheral blood mononuclear cells [1].

‍

These models yield robust HLA-restricted, epitope-specific CTL responses, validating their utility in vaccine development and immunotherapy studies. Technological sophistication extends further with double HLA knock-in mice, which carry two distinct HLA alleles simultaneously—such as HLA-A2402 and A0301—allowing researchers to model polygenic immune responses and test broadly protective vaccines in a genetically diverse context.

‍

Class II knock-in models have made similar strides. The HLA-DQ2.5 knock-in mouse, for instance, was developed by replacing murine MHC class II genes on a C57BL/6 background with human HLA-DQA105:01 and HLA-DQB102:01 alleles. These mice retain physiological expression patterns that superimpose on endogenous H2-IA expression, thus avoiding the expression artifacts seen in traditional transgenic systems. Functionality is demonstrated through successful T cell development and antigen presentation to HLA-DQ2.5-restricted, gluten-specific T cells, making them powerful models for autoimmune diseases such as celiac disease, type 1 diabetes, and lupus [2].

‍

Further enhancing immune fidelity, researchers have refined antigen processing via the integration of human TAP transporters and LMP immunoproteasome subunits (PSMB8/9). These transgenic enhancements significantly improve the presentation of HLA-restricted peptides, especially those associated with the A3 supertype. In a functional hepatitis B model, mice expressing HLA-A11 with human TAP-LMP components exhibited enhanced antigen presentation and accelerated viral clearance compared to traditional HLA transgenics [3].

‍

A recent breakthrough is the introduction of the THX mouse model, reported in Nature Immunology (2024). These mice are generated by grafting non-γ-irradiated, genetically myeloablated Kit^W-41J immunodeficient pups with human CD34+ cord blood cells, followed by 17β-estradiol conditioning to enhance thymic education. THX mice express human MHC class I and II in the thymus, which drives the development of a highly diversified immune system—including marginal zone B cells, germinal center B cells, follicular helper T cells, and neutrophils. Critically, they support both T cell-dependent and T cell-independent antibody responses, including somatic hypermutation and class-switch recombination, which are essential for antibody maturation and vaccine evaluation [4]. The presence of well-formed lymph nodes and intestinal lymphoid structures further increases their value for mucosal immunology and systemic immune studies.

‍

Together, these models enable detailed investigation of functional human immune responses—from CTL activation and antigen processing to full antibody maturation. These capacities are further enhanced in multi-cytokine platforms like MISTRG mice (discussed in part 3), which knock-in human cytokine genes such as M-CSF, IL-3, SCF, and TPO. This enables proper development of both myeloid and lymphoid lineages, creating a supportive immune microenvironment for immuno-oncology and infectious disease studies [5].

‍

In summary, the immune-engineering advancements embedded in modern humanized mouse models enable a degree of immune fidelity previously unattainable in preclinical research. By supporting polygenic modeling, physiological antigen processing, and functional T and B cell development, these models open unprecedented avenues for translational insights in cancer immunotherapy, autoimmune disease, and vaccine design. As we will explore in subsequent installments, the integration of these immune systems with additional humanized organs and disease contexts only expands their value for next-generation biomedical innovation.

‍

‍

Missed Part 1?

‍

Start from the beginning and learn why humanized models are transforming translational research in [Part 1:  How Humanized Mouse Models Are Transforming Preclinical R&D].

‍

Up Next:

‍

Discover how multi-cytokine platforms and organ-level humanization are enabling complex disease modeling in [Part 3: Modeling Complexity – Multi-Cytokine and Multi-Organ Humanization].

1. Generation of a Novel HLA Class I Transgenic Mouse Model Carrying a Knock-in Mutation at the β2-Microglobulin Locus. Describes the creation of monochain HLA class I knock-in mice with β2M linkage for physiologically relevant immune responses.
2. Generation of an HLA-DQ2.5 Knock-In Mouse . Covers development of HLA class II knock-in mice for autoimmune disease modeling.
3. Improved Transgenic Mouse Model for Studying HLA Class I Antigen Presentation. Details the integration of human TAP and LMP subunits and enhanced CTL activity in hepatitis B models.
4. A Highly Efficient and Faithful MDS Patient-Derived Xenotransplantation Model for Pre-clinical Studies. Supports the discussion of MISTRG mice and their robust support of human immune cell development.
5. A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses. describes the THX mice, enabling robust human B cell development and antibody responses, advancing vaccine and immunotherapy research.